Open AccessS258: LISOCABTAGENE MARALEUCEL (LISO‐CEL) AS SECOND‐LINE THERAPY FOR R/R LARGE B‐CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY
Author(s) -
Sehgal A.,
Hoda D.,
Riedell P. A.,
Ghosh N.,
Hamadani M.,
Hildebrandt G. C.,
Godwin J. E.,
Reagan P.,
WagnerJohnston N.,
Essell J.,
Nath R.,
Solomon S. R.,
Champion R.,
Licitra E.,
Fanning S.,
Gupta N.,
Dubowy R.,
D'Andrea A.,
Wang L.,
Gordon L. I.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843924.40372.62
Subject(s) - medicine , common terminology criteria for adverse events , fludarabine , adverse effect , cytokine release syndrome , hematopoietic stem cell transplantation , oncology , transplantation , cyclophosphamide , chemotherapy , cancer , chimeric antigen receptor , immunotherapy